These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

393 related articles for article (PubMed ID: 32034693)

  • 21. Novel treatment options for acute hepatic porphyrias.
    Wang B
    Curr Opin Gastroenterol; 2021 May; 37(3):194-199. PubMed ID: 33769375
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hyperhomocysteinemia in acute hepatic porphyria (AHP) and implications for treatment with givosiran.
    Ventura P; Sardh E; Longo N; Balwani M; Plutzky J; Gouya L; Phillips J; Rhyee S; Fanelli MJ; Sweetser MT; Petrides PE
    Expert Rev Gastroenterol Hepatol; 2022 Sep; 16(9):879-894. PubMed ID: 35929959
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Severe homocysteinemia in two givosiran-treated porphyria patients: is free heme deficiency the culprit?
    Petrides PE; Klein M; Schuhmann E; Torkler H; Molitor B; Loehr C; Obermeier Z; Beykirch MK
    Ann Hematol; 2021 Jul; 100(7):1685-1693. PubMed ID: 34050373
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Case Report: Lack of Response to Givosiran in a Case of ALAD Porphyria.
    Graff E; Anderson KE; Levy C
    Front Genet; 2022; 13():867856. PubMed ID: 35991568
    [No Abstract]   [Full Text] [Related]  

  • 25. Challenges in diagnosis and management of acute hepatic porphyrias: from an uncommon pediatric onset to innovative treatments and perspectives.
    Marcacci M; Ricci A; Cuoghi C; Marchini S; Pietrangelo A; Ventura P
    Orphanet J Rare Dis; 2022 Apr; 17(1):160. PubMed ID: 35392955
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Acute hepatic and erythropoietic porphyrias: from ALA synthases 1 and 2 to new molecular bases and treatments.
    Manceau H; Gouya L; Puy H
    Curr Opin Hematol; 2017 May; 24(3):198-207. PubMed ID: 28118224
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hypothesis: Metabolic targeting of 5-aminolevulinate synthase by tryptophan and inhibitors of heme utilisation by tryptophan 2,3-dioxygenase as potential therapies of acute hepatic porphyrias.
    Badawy AA
    Med Hypotheses; 2019 Oct; 131():109314. PubMed ID: 31443750
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Current and innovative emerging therapies for porphyrias with hepatic involvement.
    Fontanellas A; Ávila MA; Anderson KE; Deybach JC
    J Hepatol; 2019 Aug; 71(2):422-433. PubMed ID: 31102718
    [TBL] [Abstract][Full Text] [Related]  

  • 29. RNAi-mediated silencing of hepatic Alas1 effectively prevents and treats the induced acute attacks in acute intermittent porphyria mice.
    Yasuda M; Gan L; Chen B; Kadirvel S; Yu C; Phillips JD; New MI; Liebow A; Fitzgerald K; Querbes W; Desnick RJ
    Proc Natl Acad Sci U S A; 2014 May; 111(21):7777-82. PubMed ID: 24821812
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Givosiran in acute intermittent porphyria: A personalized medicine approach.
    Poli A; Schmitt C; Moulouel B; Mirmiran A; Talbi N; Rivière S; Cerutti D; Bouchoule I; Faivre A; Grobost V; Douillard C; Duchêne F; Fiorentino V; Dupré T; Manceau H; Peoc'h K; Puy H; Lefebvre T; Gouya L
    Mol Genet Metab; 2022 Mar; 135(3):206-214. PubMed ID: 35058124
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Normal reference ranges for urinary δ-aminolevulinic acid and porphobilinogen levels.
    Agarwal S; Habtemarium B; Xu Y; Simon AR; Kim JB; Robbie GJ
    JIMD Rep; 2021 Jan; 57(1):85-93. PubMed ID: 33473344
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Homocysteine elevation in givosiran treatment: Suggested ALAS1 siRNA effect on cystathionine beta-synthase.
    Vassiliou D; Sardh E
    J Intern Med; 2021 Oct; 290(4):928-930. PubMed ID: 34184789
    [No Abstract]   [Full Text] [Related]  

  • 33. Effectiveness and tolerability of givosiran for the management of acute hepatic porphyria: A monocenter real-life evaluation.
    Guida CC; Nardella M; Del Mar Ys Perez A; Savino M; Ferrara G; Napolitano F; Crisetti A; Aucella F; Aucella F
    Mol Genet Metab Rep; 2024 Sep; 40():101111. PubMed ID: 39027010
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preventing hyperhomocysteinemia using vitamin B
    Redonnet-Vernhet I; Mercié P; Lebreton L; Blouin JM; Bronnimann D; Mesli S; Guibet C; Ribeiro E; Gensous N; Duffau P; Gouya L; Richard E
    Mol Genet Metab Rep; 2024 Jun; 39():101076. PubMed ID: 38601120
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost savings with hemin versus givosiran for the treatment of patients with acute intermittent porphyria (AIP).
    Massachi S; Epstein J; Hurd J; Bonkovsky HL
    J Med Econ; 2020 Dec; 23(12):1441-1449. PubMed ID: 33043761
    [TBL] [Abstract][Full Text] [Related]  

  • 36. EXPLORE: A Prospective, Multinational, Natural History Study of Patients with Acute Hepatic Porphyria with Recurrent Attacks.
    Gouya L; Ventura P; Balwani M; Bissell DM; Rees DC; Stölzel U; Phillips JD; Kauppinen R; Langendonk JG; Desnick RJ; Deybach JC; Bonkovsky HL; Parker C; Naik H; Badminton M; Stein PE; Minder E; Windyga J; Bruha R; Cappellini MD; Sardh E; Harper P; Sandberg S; Aarsand AK; Andersen J; Alegre F; Ivanova A; Talbi N; Chan A; Querbes W; Ko J; Penz C; Liu S; Lin T; Simon A; Anderson KE
    Hepatology; 2020 May; 71(5):1546-1558. PubMed ID: 31512765
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Zinc mesoporphyrin represses induced hepatic 5-aminolevulinic acid synthase and reduces heme oxygenase activity in a mouse model of acute hepatic porphyria.
    Schuurmans MM; Hoffmann F; Lindberg RL; Meyer UA
    Hepatology; 2001 May; 33(5):1217-22. PubMed ID: 11343251
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recovery of chronic motor neuropathy due to acute intermittent porphyria after givosiran treatment in a young boy: a case report.
    Mazzoli M; Ricci A; Vaudano AE; Marcacci M; Marchini S; Bergonzini P; Di Pierro E; Pischik E; Iughetti L; Pietrangelo A; Meletti S; Ventura P
    Eur Rev Med Pharmacol Sci; 2024 Apr; 28(8):3268-3274. PubMed ID: 38708485
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Givosiran - Running RNA Interference to Fight Porphyria Attacks.
    Gonzalez-Aseguinolaza G
    N Engl J Med; 2020 Jun; 382(24):2366-2367. PubMed ID: 32521139
    [No Abstract]   [Full Text] [Related]  

  • 40. Biochemical Diagnosis of Acute Hepatic Porphyria: Updated Expert Recommendations for Primary Care Physicians.
    Anderson KE; Lobo R; Salazar D; Schloetter M; Spitzer G; White AL; Young RM; Bonkovsky HL; Frank EL; Mora J; Tortorelli S
    Am J Med Sci; 2021 Aug; 362(2):113-121. PubMed ID: 33865828
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.